Key Highlights

  • Shares are trading up 6.05% intraday to $82.59, from a prior close of $77.88
  • Launched a new online offering to expand accessibility of exome testing for children with developmental delay, intellectual disability, or epilepsy
  • Second quarter 2026 Revenue was $114.4 million, up 17% year over year, with exome and genome test Volume growth of 32%
  • Company returned to profitability one quarter ahead of plan, with Net Income of $0.4 million
  • New offering allows families to initiate testing directly from GeneDx.com, connecting with licensed healthcare providers
  • Broader rotation into healthcare and biotech names has coincided with continued strength in the stock
  • Market Capitalization stands at $2.46 billion, with a 52-week range of $32.21 to $170.87

Shares Rise on New Testing Access Initiative

GeneDx Holdings (NASDAQ:WGS) shares are trading up 6.05% intraday to $82.59, from a prior close of $77.88. The move follows the company's announcement of a new online offering designed to expand accessibility of exome testing at scale for pediatric patients with global developmental delay, intellectual disability, or epilepsy, allowing families to initiate genetic testing directly from GeneDx.com.

The new offering connects families directly with licensed healthcare providers who can review medical information, order testing, and deliver results without requiring traditional in-person visits, addressing a documented access gap where about 25% of pediatric patients wait more than a year and about 50% wait more than six months for a clinical genetics appointment.

What GeneDx Holdings Does

GeneDx Holdings, headquartered in Stamford, Connecticut, is a global leader in rare disease diagnosis, providing genetic testing services with a primary focus on pediatric and rare disease diagnostics through whole exome and genome sequencing. The company holds an estimated 35% to 40% share of the U.S. pediatric whole exome sequencing market, leveraging a proprietary database of over 600,000 clinical exomes that delivers a diagnostic rate of approximately 38%, significantly above the industry average.

GeneDx also develops an AI-based platform for next-generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing, using its Fabric Genomics Subsidiary specializing in AI-powered genomic interpretation. Under the Leadership of Chief Executive Officer Katherine A. Stueland, the company serves more than 4,000 health systems globally and reported trailing twelve-month revenues of approximately $362 million.

Momentum From Strong Second Quarter Results

The new testing access initiative builds on strong second quarter 2026 results released last week, in which revenue grew 17% year over year to $114.4 million, driven by exome and genome test volume growth of 32%. The company returned to profitability one quarter ahead of its own plan, reporting net income of $0.4 million, a meaningful improvement from the prior-year period.

The stock's continued rally also comes amid a broader rotation into healthcare and biotech names, with the sector outperforming the market over the past three months as investors respond to improving fundamentals across a historically underperforming group. GeneDx's combination of accelerating volume growth, improved profitability, and expanded market access appears to be resonating with investors navigating this sector rotation.

Conclusion

GeneDx Holdings' intraday gain reflects investor enthusiasm for the company's new testing access initiative, which builds on already strong second quarter results showing accelerating volume growth and an earlier-than-planned return to profitability. With the broader healthcare and biotech sector attracting renewed investor interest and the company's core exome testing Business continuing to scale, the new online offering appears to reinforce rather than distract from the underlying growth story that has driven the stock's rally in recent months.